Health and Healthcare
Diabetes Drug Approved For Europe (AMLN, LLY)
Published:
Last Updated:
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) and Eli Lilly & Co. (NYSE: LLY) are in the news on the diabetes front. The companies have announced that the European Commission has now approved its Type-2 Diabetes treatment Byetta as an add-on therapy to basal insulin.
As a reminder, Amylin agreed to pay $250 million to Lilly as well as milestones of up to $1.2 billion for the molecule that makes up Byetta. Amylin also confirmed that it will be responsible for the commercialization of Byetta outside of the United States. Amylin is still working with Lilly during the transition period through 2013.
Amylin shares have not responded so far this morning and the indications have not been matched with any real share volume. At $15.51, the 52-week range is $8.03 to $18.45.
Amylin currently has a market capitalization rate of $2.27 billion as of now and the company is expected to lose money in 2012 and 2013 even though revenues are expected to be about $681 million and $837 million for 2012 and 2013, respectively.
JON C. OGG
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
